Development of a selectively AURKB targeting peptide degradation drug with artificial intelligence-assisted design for the treatment of acute lymphoblastic leukemia.

INTRODUCTION: Acute lymphoblastic leukemia (ALL) is a highly heterogeneous hematologic malignancy with poor prognosis in refractory and relapsed cases. Aurora kinase B (AURKB), a member of the Aurora kinase family, is markedly overexpressed in ALL pa…

Preview only. Read the full abstract at the source